Screener
Ironwood Pharmaceuticals IRWD Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
FAQ
- What is Ironwood Pharmaceuticals's retained earnings?
- Ironwood Pharmaceuticals (IRWD) reported retained earnings of -$1.58B in Q2 2026.
- How has Ironwood Pharmaceuticals's retained earnings changed year-over-year?
- Ironwood Pharmaceuticals's retained earnings increased by 7.6% year-over-year, from -$1.71B to -$1.58B.
- What is the long-term trend for Ironwood Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Ironwood Pharmaceuticals's retained earnings has grown at a 2.7% compound annual growth rate (CAGR), from -$1.47B to -$1.67B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Ironwood Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude